The Rubinstein-Taybi syndrome (RTS) is a rare autosomal-dominant disease associated with 10-15% of cases with 16p13.3 microdeletions involving the CREB-binding protein gene (CREBBP). We used arraycomparative genomic hybridization and Quantitative multiplex fluorescent-PCR (QMF-PCR) to search for dosage anomalies in the 16p13.3 region and the CREBBP gene. We first constructed a microarray covering 2 Mb that carries seven BAC and 34 cosmid clones, as well as 26 low-molecular-weight probes (1000-1500 bp) that are spread along the CREBBP gene. To increase further the resolution inside the CREBBP gene, we used QMF-PCR assays providing a 7 kb resolution. The deletions characterized in this work extended between as little as 3.3 kb and 6.5 Mb. Some deletions were restricted to just a few exons of CREBBP, some deleted either the 5 0 or the 3 0 end of the gene plus adjacent genomic segments, others deleted the whole gene away. We also identified a duplication of exon 16. We showed that CREBBP dosage anomalies constitute a common cause of RTS. CREBBP high-resolution gene dosage search is therefore highly recommended for RTS diagnosis. No correlation was found between the type of deletion and the patients' phenotype. All patients had typical RTS, and there was no particular severity associated with certain alterations.
Introduction
The Rubinstein -Taybi syndrome (RTS, [MIM 180849] ) is an autosomal-dominant disease that occurs in 1/125 000 births and is characterized by growth retardation and psychomotor development delay, broad and duplicated distal phalanges of thumbs and halluces, a typical facial dysmorphism and an increased tumoral risk. 1 RTS is due to mutations in the CREB-binding protein gene (CREBBP commonly referred to by its shorter acronym CBP).
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Microdeletions including the CREBBP gene are known to account for about 10 -15% of RTS cases. 2,5 -7 Our latter study 7 clearly showed that CREBBP deletions are heterogeneous in size as well as in position in the gene, since some delete the whole of the CREBBP gene as well as flanking regions away, while others are restricted to intragenic segments.
To perform a comprehensive search for both large and small deletions in patients with the RTS, we have now used two complementary techniques: comparative genomic hybridization on microarrays (array-CGH) 8 and quantitative multiplex fluorescent-PCR (QMF-PCR). 9 Our data show that gene dosage anomalies of the CREBBP gene span between 3.3 kb and 6.5 Mb, and constitute a more common cause of RTS than was initially thought.
Materials and methods

Rubinstein -Taybi syndrome patients
Patients expressed a typical RTS phenotype, assessed by a detailed clinical questionnaire, photographs, X-rays, and medical records. This study followed ethical guidelines and was authorized by the Comité pour la Protection des Personnes (CPP) of Bordeaux. (T1, T2, T3, T4, T5, T6, T7) are available from the authors.
Low-molecular-weight clones Twenty-eight repeat-free targets named aCBPx ranging in size from 1000 to 1500 pb were selected after masking the repeated sequences using the repeat masker software (http://www.repeatmasker. org/cgi-bin/WEBRepeatMasker/) (see Supplementary Table 1 for targets' characteristics). Targets located centromeric to AC020663 are presented in Supplementary Table 2 . Seventeen control targets (C1-C17) were selected in various genomic regions (details available from the authors). Microarray manufacturing and analysis was described by Stef et al 13 for low-molecular-weight (LMW) targets;
procedures for high-molecular-weight (HMW) targets are available from the authors. Each target was represented at least eight times on the array. Microarrays were scanned with a G2565B scanner (Agilent Technologies). Normalization of values obtained was done using controls T1 -T7 for the HMW clones and using controls C1 -C17 for the LMW clones.
Quantitative multiplex fluorescent PCR Twenty-nine PCR assays were designed within a 203 kb interval that includes the CREBBP gene (Supplementary Figure 1 and Supplementary Table 1) . Array-comparative genomic hybridization (array-CGH) was used to characterize further large deletions that had previously been observed (patients p4, p9, p31, p34, p59, p73, p197) 3, 7 and to identify new ones (patients p218, p219). DNA of RTS patients was hybridized against DNA from a patient (CG) harbouring an 11q14.3 deletion 12 as an internal deletion control. Results obtained are shown in Table 1 (HMW targets), and in Supplementary Table 5 (LMW targets). See Supplementary Figure 2 for representative examples of microarray results. Deletions were very heterogeneous in size and position. We were able to determine the extent of most of them. Deletions removing entirely the CREBBP gene plus flanking segments were observed in patients p219 (about 590 kb) and p59 (about 860 kb).
The farthest centromeric BAC clone (AC020663) was deleted in patients p4 and p218. We therefore designed additional LMW targets at increasing distances from AC020663 towards the centromere (Supplementary materials Table 2 ). In patient p218, the deletion breakpoint was between LMW 6.42 and LMW 7.45 (Supplementary materials Table 6) , that is in an interval located between 2560 and 3550 kb away from exon 1 of the CREBBP gene. The deletion therefore encompassed between 2.4 and 3.9 Mb. In patient p4, the deletion breakpoint laid between LMW 10.1 and 10.2 (Supplementary materials Table 6 ). This deletion therefore encompassed about 6.5 Mb. These data were confirmed by quantitative multiplex fragment-PCR 9 assays derived inside the LMW targets (data not shown).
Identification of small intragenic rearrangements
The microarray clearly showed the existence of deletions limited to one or two cosmids in some patients. This suggested that even smaller rearrangements might be identified. Indeed a deletion of a single target, aCBP10, was found in patient p7 (Supplementary Table 5 ). We therefore turned to quantitative multiplex PCR, a less expensive approach than array-CGH, to search for small rearrangements. Twenty-nine PCR assays (named qCBP2 to qCBP21; see Supplementary Figure 1e ) were designed over a 203 kb genomic segment including the CREBBP gene, allowing us to reach a 7 kb resolution inside the gene. The assays were grouped into four multiplex PCR sets (Supplementary Table 4 ). Twenty patients with characteristic features of RTS in whom no point mutation had been identified in spite of a comprehensive investigation were then analysed. Deletions were identified in patients p15, p20, p115, p246, and a duplication in patient p62 (Table 2) . These data were confirmed by array-CGH analysis (see Supplementary  Figure 3 for patients p15, p20, p62). All of the deletions observed were small, and took between one and three exons away. The duplication in patient p62 contains exon 16. RT-PCR analysis, followed by both restriction and sequence analysis, indicated that exon 16 is duplicated in tandem in the CREBBP RNA (r.3259 -3448dup) (data not shown). This duplication introduces a frameshift in the translation, with the appearance of a stop codon at the 13th codon into the second copy of exon 16 (P.Ile1084Asn AC007151  AC005564  AC004495  AC004509  AC004651  RT100  AC004760  AC005203  AC005607  AC004645  AC004496  AC004644  AC004494  AC005590  AC004646  AC005362  AC004035  AC003966  AC025283  AC004232  AC108134  AC004233  AC004235  AC004034  AC004234  AC005361 AC005570 AC004493 AC007151  AC005564  AC004495  AC004509  AC004651  RT100  AC004760  AC005203  AC005607  AC004645  AC004496  AC004644  AC004494  AC005590  AC004646  AC005362  AC004035  AC003966  AC025283  AC004232  AC108134  AC004233  AC004235  AC004034  AC004234  AC005361  AC005570  AC004493   p7  p31  p34  p73 + + + + + + + + + + p197 p9 p219 p59 p4
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Abbreviation: array-CGH, array comparative genomic hybridization. Targets are oriented from the centromere to the 16p telomere. The CREBBP gene region is in grey. Deleted targets are indicated by À, whereas not deleted targets are indicated by +.
fsX13). This duplication hence leads to a truncated CREBBP protein that lacks the second half of the protein.
Discussion
We have used array-CGH and QMF-PCR to find gene dosage anomalies of the CREBBP gene and the surrounding 16p13. 3 region in patients with RTS. Our results show that deletion sizes extend from just a few kilobase pairs (3.3 kb in patient p7; data not shown) to 2400 -3900 kb in patient p218 and about 6.5 Mb in patient p4. A small deleterious duplication was identified in one patient. Deletions are very heterogeneous in size and in position with respect to the CREBBP gene. These data are summarized in Figure 1 . Out of the 21 patients analysed (without a previously identified CREBBP mutation), six were found to have an interstitial gene dosage anomaly (ie 28.6%). Among a total of 83 patients with typical features of RTS analysed in our laboratory, the proportion of patients with a deletion was now estimated to be 20.5% (17/83). The CREBBP rearrangements must therefore be searched for by any kind of costeffective technique such as QMF-PCR, or others (eg the ligation-based MLPA 14 or QMPSF 15 ) before a lengthy search for other mutations of CREBBP or of its homologue P300 16 is undertaken.
We did not find a phenotypic difference between patients with small or large deletions, and with deletions extending either towards centromeric or telomeric regions with respect to CREBBP. The only noticeable event is that patient p4 who had the largest deletion (6.5 Mb removing the CREBBP gene plus a large centromeric segment) had a very severe form of the disease with choanal atresia, bilateral dilated ureters, hemivertebrae (T9, T11) and hypoplastic vertebrae (T10, T12), and deceased at 34 days of life. AC004235  AC004647  AC005568  AC004653  AC005356  AC005222  AC004750  AC004778  AC005211  AC004789  AC004493  AC005570  AC005361  AC004234  AC004034  AC004233  AC004232  AC003966  AC005362  AC004646  AC004035  AC005590  AC004494  AC004644  AC004496  AC004645  AC005607  AC005203  AC004760  AC004651 Particular attention was paid to the phenotype of patients p59 and p218 with a deletion including the DNAseI gene located 62 kb on the telomeric side of CREBBP, since Bartsch et al 11 described a particularly severe phenotype with a proneness to repeated infections in patients with a deletion of this gene. Both patients have a rather severe, yet typical, form of RTS (facial dysmorphism, abnormalities of the extremities, mental retardation). Patient p59 is a 39-year-old adult with a small size (132 cm), renal agenesis, radial dislocation, and predisposition to tumours (Hodgkins lymphoma, ovarians cysts, numerous spontaneaous and surgical cheloids, pilomatrixoma). Patient p218 has cardiac (atrial septal defect, patent ductus arteriosus), renal (vesical ureteral reflux) and skeletal (pectus excavatum) malformations. All these features, however, have been described in other RTS patients, including patients with CREBBP point mutations. These patients did not have a particularly severe mental retardation, nor were they particularly prone to infections. It is noteworthy that patient p59 did not develop infections after chemotherapy of her Hodgkins lymphoma. The presentation of these two patients therefore does not confirm the phenotype described by Bartsch et al. 
